These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8229737)

  • 1. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.
    Trippodo NC; Fox M; Natarajan V; Panchal BC; Dorso CR; Asaad MM
    J Pharmacol Exp Ther; 1993 Oct; 267(1):108-16. PubMed ID: 8229737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
    Seymour AA; Asaad MM; Lanoce VM; Langenbacher KM; Fennell SA; Rogers WL
    J Pharmacol Exp Ther; 1993 Aug; 266(2):872-83. PubMed ID: 8394922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
    Trippodo NC; Panchal BC; Fox M
    J Pharmacol Exp Ther; 1995 Feb; 272(2):619-27. PubMed ID: 7853175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Rogers WL; Dorso CR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
    J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of endopeptidase 24.11 inhibition in conscious cardiomyopathic hamsters.
    Smits GJ; McGraw DE; Trapani AJ; Blaine EB
    J Pharmacol Exp Ther; 1990 Jul; 254(1):176-9. PubMed ID: 2142219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.
    Rademaker MT; Charles CJ; Cooper GJ; Coy DH; Espiner EA; Lewis LK; Nicholls MG; Richards AM
    Clin Sci (Lond); 2002 Jun; 102(6):653-60. PubMed ID: 12049620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
    Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
    Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure.
    Binkley PF; Nunziata E; Haas GJ; Starling RC; Leier CV; Cody RJ
    Am Heart J; 2000 Jul; 140(1):34-42. PubMed ID: 10874261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs.
    Seymour AA; Sheldon JH; Smith PL; Asaad M; Rogers WL
    J Pharmacol Exp Ther; 1994 Apr; 269(1):263-70. PubMed ID: 8169834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic and regional hemodynamic effects of a new angiotensin converting enzyme and neutral endopeptidase mixed inhibitor, alatriopril, in the dog].
    Richard V; Lecomte JM; Thuillez C
    Arch Mal Coeur Vaiss; 1993 Aug; 86(8):1275-9. PubMed ID: 8129543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
    Gonzalez W; Beslot F; Laboulandine I; Fournié-Zaluski MC; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1996 Aug; 278(2):573-81. PubMed ID: 8768706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP
    Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.